Association of Chlamydia trachomatis Infection and Herpes Simplex Virus Type 2 Serostatus With Genital Human Papillomavirus Infection in Men: The HPV in Men Study

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorALBERTS, Catharina Johanna
dc.contributor.authorLOEFF, Maarten F. Schim van der
dc.contributor.authorPAPENFUSS, Mary R.
dc.contributor.authorSILVA, Roberto Jose Carvalho da
dc.contributor.authorVILLA, Luisa Lina
dc.contributor.authorLAZCANO-PONCE, Eduardo
dc.contributor.authorNYITRAY, Alan G.
dc.contributor.authorGIULIANO, Anna R.
dc.date.accessioned2013-09-23T16:37:31Z
dc.date.available2013-09-23T16:37:31Z
dc.date.issued2013
dc.description.abstractBackground: Studies in women indicate that some sexually transmitted infections promote human papillomavirus (HPV) persistence and carcinogenesis. Little is known about this association in men; therefore, we assessed whether Chlamydia trachomatis (CT) infection and herpes simplex virus type 2 (HSV-2) serostatus are associated with genital HPV prevalence, an early event in HPV-related pathogenesis. Methods: Genital exfoliated cells, first-void urine, and blood from 3971 men recruited in the United States, Mexico, and Brazil were tested for HPV, CT, and HSV-2 antibodies, respectively. Multivariable logistic regression was used to assess the association of CT infection and HSV-2 serostatus with 4 HPV outcomes (any, oncogenic, nononcogenic only, and multiple infections). Results: A total of 64 (1.6%) men were CT positive, and 811 (20.4%) men were HSV-2 seropositive. After adjustment for potential confounders, CT was associated with any HPV (adjusted odds ratio [aOR], 2.19; 95% confidence interval [CI], 1.13-4.24), oncogenic HPV (aOR, 3.10; 95% CI, 1.53-6.28), and multiple HPV (aOR, 3.43; 95% CI, 1.69-6.95) prevalence. Herpes simplex virus type 2 serostatus was associated with any HPV (aOR, 1.25; 95% CI, 1.02-1.52), nononcogenic HPV only (aOR, 1.38; 95% CI, 1.08-1.75), and multiple HPV (aOR, 1.33; 95% CI, 1.06-1.68) prevalence. In analyses stratified by sexual behavior, CT infection was significantly associated with HPV detection among men reporting 2 or more recent sexual partners, whereas HSV-2 serostatus was significantly associated with HPV detection in men reporting 0 to 5 lifetime sexual partners. Conclusion: In this population, CT infection and HSV-2 serostatus were associated with prevalent genital HPV infection. Future prospective studies should investigate whether these infections influence HPV acquisition and/or persistence.
dc.description.indexMEDLINE
dc.description.sponsorshipNational Cancer Institute, US National Institutes of Health (NIH) [CA R01CA098803]
dc.description.sponsorshipMerck
dc.description.sponsorshipSanofi-Pasteur MSD
dc.description.sponsorshipGSK
dc.identifier.citationSEXUALLY TRANSMITTED DISEASES, v.40, n.6, p.508-515, 2013
dc.identifier.doi10.1097/OLQ.0b013e318289c186
dc.identifier.issn0148-5717
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1879
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofSexually Transmitted Diseases
dc.rightsrestrictedAccess
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINS
dc.subject.otherinvasive cervical-cancer
dc.subject.otherrisk-factors
dc.subject.otherprevalence
dc.subject.othercohort
dc.subject.otherwomen
dc.subject.otheradolescents
dc.subject.otherpersistence
dc.subject.otherneoplasia
dc.subject.othercofactor
dc.subject.otherincident
dc.subject.wosInfectious Diseases
dc.titleAssociation of Chlamydia trachomatis Infection and Herpes Simplex Virus Type 2 Serostatus With Genital Human Papillomavirus Infection in Men: The HPV in Men Study
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryMéxico
hcfmusp.affiliation.countryHolanda
hcfmusp.affiliation.countryisonl
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisomx
hcfmusp.author.externalALBERTS, Catharina Johanna:GGD, Amsterdam, Netherlands; Acad Med Ctr, Ctr Infect & Immun Amsterdam, Dept Internal Med, Div Infect Dis Trop Med & AIDS, Amsterdam, Netherlands
hcfmusp.author.externalLOEFF, Maarten F. Schim van der:GGD, Amsterdam, Netherlands; Acad Med Ctr, Ctr Infect & Immun Amsterdam, Dept Internal Med, Div Infect Dis Trop Med & AIDS, Amsterdam, Netherlands
hcfmusp.author.externalPAPENFUSS, Mary R.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Infect Res Canc, Tampa, FL USA
hcfmusp.author.externalSILVA, Roberto Jose Carvalho da:Ctr Referencia Treinamento DST Aids, Sao Paulo, Brazil
hcfmusp.author.externalLAZCANO-PONCE, Eduardo:Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico
hcfmusp.author.externalNYITRAY, Alan G.:Univ Texas Houston, Sch Publ Hlth, Ctr Infect Dis, Houston, TX USA
hcfmusp.author.externalGIULIANO, Anna R.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Infect Res Canc, Tampa, FL USA
hcfmusp.citation.scopus24
hcfmusp.contributor.author-fmusphcLUISA LINA VILLA
hcfmusp.description.beginpage508
hcfmusp.description.endpage515
hcfmusp.description.issue6
hcfmusp.description.volume40
hcfmusp.origemWOS
hcfmusp.origem.pubmed23680908
hcfmusp.origem.scopus2-s2.0-84878856697
hcfmusp.origem.wosWOS:000319192500017
hcfmusp.publisher.cityPHILADELPHIA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAnttila T, 2001, JAMA-J AM MED ASSOC, V285, P47, DOI 10.1001/jama.285.1.47
hcfmusp.relation.referenceArnheim DL, 2011, CANCER EPIDEM BIOMAR, V20, P2541
hcfmusp.relation.referenceBouvard V, 2009, LANCET ONCOL, V10, P321
hcfmusp.relation.referenceCastellsague X, 2002, VIRUS RES, V89, P191, DOI 10.1016/S0168-1702(02)00188-0
hcfmusp.relation.referenceCastle PE, 2003, SEX TRANSM DIS, V30, P575, DOI 10.1097/00007435-200307000-00009
hcfmusp.relation.referenceCastle PE, 2003, J NATL CANC I MONOGR, V31, P29
hcfmusp.relation.referenceGiuliano AR, 2009, INT J CANCER, V124, P1251, DOI 10.1002/ijc.24097
hcfmusp.relation.referenceGiuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
hcfmusp.relation.referenceGravitt PE, 2000, J CLIN MICROBIOL, V38, P357
hcfmusp.relation.referenceGravitt PE, 1998, J CLIN MICROBIOL, V36, P3020
hcfmusp.relation.referenceHowell-Jones R, 2012, VACCINE, V30, P3867, DOI 10.1016/j.vaccine.2012.04.006
hcfmusp.relation.referenceKim S, 2011, SEX TRANSM DIS, V38, P587, DOI 10.1097/OLQ.0b013e31820a9324
hcfmusp.relation.referenceKjaer SK, 2005, CANCER EPIDEM BIOMAR, V14, P1528, DOI 10.1158/1055-9965.EPI-04-0754
hcfmusp.relation.referenceKOFFA M, 1995, INT J CANCER, V63, P58, DOI 10.1002/ijc.2910630112
hcfmusp.relation.referenceLehtinen M, 2011, SEX TRANSM INFECT, V87, P372, DOI 10.1136/sti.2010.044354
hcfmusp.relation.referenceLehtinen M, 2002, AM J EPIDEMIOL, V156, P687, DOI 10.1093/aje/kwf098
hcfmusp.relation.referenceManavi K, 2006, BEST PRACT RES CL OB, V20, P941, DOI 10.1016/j.bpobgyn.2006.06.003
hcfmusp.relation.referenceOakeshott P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4168
hcfmusp.relation.referenceSafaeian M, 2010, J NATL CANCER I, V102, P1794, DOI 10.1093/jnci/djq436
hcfmusp.relation.referenceSamoff E, 2005, AM J EPIDEMIOL, V162, P668, DOI 10.1093/aje/kwi262
hcfmusp.relation.referenceShigehara K, 2011, J INFECT CHEMOTHER, V17, P487, DOI 10.1007/s10156-010-0203-0
hcfmusp.relation.referenceSmith JS, 2004, INT J CANCER, V111, P431, DOI 10.1002/ijc.20257
hcfmusp.relation.referenceSmith JS, 2010, INT J CANCER, V126, P572, DOI 10.1002/ijc.24770
hcfmusp.relation.referenceSmith JS, 2002, J NATL CANCER I, V94, P1604
hcfmusp.relation.referenceTran-Thanh D, 2003, AM J OBSTET GYNECOL, V188, P129, DOI 10.1067/mob.2003.66
hcfmusp.relation.referenceVeldhuijzen NJ, 2012, SEX TRANSM DIS, V39, P128, DOI 10.1097/OLQ.0b013e3182367c4c
hcfmusp.relation.referenceVriend HJ, 2012, SEX TRANSM DIS, V39, P72, DOI 10.1097/OLQ.0b013e318235b3b0
hcfmusp.relation.referenceWald A, 2002, J INFECT DIS, V186, pS34, DOI 10.1086/342969
hcfmusp.relation.referenceWald A, 2002, CLIN INFECT DIS, V35, pS173, DOI 10.1086/342104
hcfmusp.relation.referenceWHO, 2007, IARC MON EV CARC RIS, V90
hcfmusp.remissive.sponsorshipMerck
hcfmusp.remissive.sponsorshipNIH
hcfmusp.remissive.sponsorshipSanofi-Aventis
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicatione9db2534-e0d7-4b2e-b4aa-c3be7faf01d5
relation.isAuthorOfPublication.latestForDiscoverye9db2534-e0d7-4b2e-b4aa-c3be7faf01d5
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_VILLA_Association_of_Chlamydia_trachomatis_Infection_and_Herpes_Simplex_2013.PDF
Tamanho:
512 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24